MRKR
MRKR clinical trials: Marker Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Marker Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 7
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MRKR on the catalyst calendar · MRKR registry changes
- Primary completion Sep 2029Sponsor estimatePhase 1NCT06552416Safety of MT-401-OTS in Patients With Relapsed AML or MDSMarker Therapeutics, Inc. · Acute Myeloid Leukemia, in RelapseRecruitingMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2028Sponsor estimatePhase 1NCT05798897Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaMarker Therapeutics, Inc. · Non-Hodgkin Lymphoma, AdultRecruitingMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 16, 2028Sponsor estimatePhase 1NCT06549751MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerMarker Therapeutics, Inc. · Pancreas CancerNot yet recruitingMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2024ActualPhase 2NCT04511130Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantMarker Therapeutics, Inc. · Acute Myeloid LeukemiaTerminatedMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2020ActualPhase 2NCT02978222Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian CancerMarker Therapeutics, Inc. · Platinum Sensitive Ovarian CancerTerminatedMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2021ActualNo phase registeredNCT04358003Plasma Adsorption in Patients With Confirmed COVID-19Marker Therapeutics AG · Respiratory FailureCompletedMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2021ActualPhase 2NCT02593227Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast CancerMarker Therapeutics, Inc. · Breast CancerCompletedMRKRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2021ActualPhase 2NCT02764333TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant...Memorial Sloan Kettering Cancer Center · Ovarian CancerCompletedMRKRCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2014ActualPhase 1NCT01632332Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast CancerMayo Clinic · HER2-positive Breast CancerCompletedMRKRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner